Delving into the Latest Updates on E-CEL UVEC with Synapse

Overview

Basic Info

Drug Type

Gene therapy, Stem cell therapy

Synonyms-

Target-

Action-

Mechanism

Cell replacements

Therapeutic Areas

Nervous System DiseasesDigestive System DisordersSkin and Musculoskeletal Diseases+ [1]

Active Indication

Perianal fistulaFissure in AnoMuscular Atrophy+ [2]

Inactive Indication-

Originator Organization

Angiocrine Bioscience, Inc.

Active Organization

Angiocrine Bioscience, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This clinical trial is being conducted by investigators who are colorectal surgeons. Eligible study participants will receive the experimental treatment E-CEL UVEC cells by direct injection into the anal fissure. The study is being conducted to determine if E-CEL UVEC cell injections will be safe and would have any effects on healing of the anal fissure.

Start Date12 Sep 2024

Sponsor / Collaborator

Weill Medical College of Cornell University

[+1]

NCT04190862

/ RecruitingPhase 1IIT

An Open-Label, Single-Center, Investigator Initiated Phase 1B Trial of E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

The purpose of this study is to determine if endothelial cells derived from human umbilical vein are safe for use in conjunction with fistulotomy for the treatment of simple anal fistulas. Endothelial cells are a special kind of cell in the body that line the inside surface of blood vessels. The goal of the study is to evaluate the preliminary safety of human umbilical vein cells in anal fistula healing.

Start Date22 Jan 2020

Sponsor / Collaborator

Weill Medical College of Cornell University

[+1]

100 Clinical Results associated with E-CEL UVEC

Login to view more data

100 Translational Medicine associated with E-CEL UVEC

Login to view more data

100 Patents (Medical) associated with E-CEL UVEC

Login to view more data

100 Deals associated with E-CEL UVEC

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Perianal fistula	Phase 2	United States	Angiocrine Bioscience, Inc.	01 May 2027
Fissure in Ano	Phase 1	United States	Angiocrine Bioscience, Inc.	12 Sep 2024
Muscular Atrophy	Phase 1	United States	Angiocrine Bioscience, Inc.	20 Nov 2019
Rotator cuff syndrome	Phase 1	United States	Angiocrine Bioscience, Inc.	20 Nov 2019
Rotator Cuff Tendinitis	Phase 1	United States	Angiocrine Bioscience, Inc.	20 Nov 2019